Sarah Kimuda
YOU?
Author Swipe
View article: Cerebrospinal fluid transcriptional immune pathways linked to survival in HIV-associated tuberculous meningitis
Cerebrospinal fluid transcriptional immune pathways linked to survival in HIV-associated tuberculous meningitis Open
BACKGROUND TB meningitis (TBM) has up to 50% mortality in people living with HIV. We investigated differences in cerebrospinal fluid (CSF) host immune responses associated with acute mortality. METHODS We enrolled a prospective cohort of a…
View article: CSF Hypo-Inflammation Drives Mortality in HIV-Associated Tuberculous Meningitis
CSF Hypo-Inflammation Drives Mortality in HIV-Associated Tuberculous Meningitis Open
Background: Excessive CNS inflammation is associated with poor outcomes in tuberculous meningitis (TBM). Anti–inflammatory corticosteroid therapy improves survival in HIV–negative TBM, but not in people with HIV. In people with HIV, TBM is…
View article: Evolving Epidemiology, Improving Diagnostic Tests and Their Importance for the Correct Diagnosis of Histoplasmosis
Evolving Epidemiology, Improving Diagnostic Tests and Their Importance for the Correct Diagnosis of Histoplasmosis Open
Histoplasmosis has traditionally been described as having discrete geographic areas of endemicity. Over the last few decades, it has become more and more clear that these areas are not accurate depictions of where histoplasmosis can occur.…
View article: Evolution of Laboratory Diagnostics for Cryptococcosis and Missing Links to Optimize Diagnosis and Outcomes in Resource-Constrained Settings
Evolution of Laboratory Diagnostics for Cryptococcosis and Missing Links to Optimize Diagnosis and Outcomes in Resource-Constrained Settings Open
Cryptococcal meningitis is one of the leading causes of death in sub-Saharan Africa among patients with advanced HIV disease. Early diagnosis is crucial in improving treatment outcomes. Despite advances and the availability of modern and p…
View article: 5-Flucytosine Longitudinal Antifungal Susceptibility Testing of <i>Cryptococcus neoformans</i>: A Substudy of the EnACT Trial Testing Oral Amphotericin
5-Flucytosine Longitudinal Antifungal Susceptibility Testing of <i>Cryptococcus neoformans</i>: A Substudy of the EnACT Trial Testing Oral Amphotericin Open
Background The EnACT trial was a phase 2 randomized clinical trial conducted in Uganda, which evaluated a novel orally delivered lipid nanocrystal (LNC) amphotericin B in combination with flucytosine for the treatment of cryptococcal menin…
View article: 1490. Predictors of Early Mortality in HIV-associated Tuberculous Meningitis
1490. Predictors of Early Mortality in HIV-associated Tuberculous Meningitis Open
Background Tuberculous meningitis (TBM) mortality averages at 27% but may reach 70% in HIV co-infection. High MRC severity grade, lower cerebrospinal fluid (CSF) white blood cell count (WBC) count, low weight, low CD4 and low plasma sodium…
View article: Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis
Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis Open
View article: Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial
Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial Open
Background Amphotericin B is the gold standard treatment for severe mycoses. A new orally delivered, less-toxic formulation of amphotericin has been developed. Methods In our randomized clinical trial, we tested oral lipid nanocrystal (LNC…